MiR-506 suppresses papillary thyroid carcinoma cell proliferation and metastasis via targeting IL17RD.
CONCLUSIONS: In this study, we found that miR-506 could inhibit the proliferation and metastasis of PTC cells. Meanwhile, IL17RD might be a downstream target of the biological process. Our findings provided a new therapeutic direction for the treatment of PTC.
PMID: 31002136 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research
More News: Cancer & Oncology | Carcinoma | Drugs & Pharmacology | Genetics | Study | Thyroid | Thyroid Cancer